L'intérêt à découvert pour Abbott Laboratories donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Abbott Laboratories. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Abbott Laboratories (NYSE:ABT) Stock, Rapport sur les intérêts à découvert

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

On Thursday, Dexcom, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) fourth-quarter&nbsp;revenue rose 8% year-over-year to&nbsp;$1.114 billion,&nbsp;beating the analyst consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of&nbsp;$1.104 billion</a>.
U.S. revenue rose by 4%, while international revenue rose by 17% on a reported basis and <a target="_blank" href="https://www.benzinga.com/25/02/43728537/dexcom-tops-sales-forecasts-as-international-growth-soars-19" rel="noreferrer noopener">19% on an organic basis</a>.
Outlook: Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> adjusted operating margin of 21%</a>.
In December, Abbott Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reached an agreement with DexCom to settle all outstanding patent disputes related to continuous glucose monitoring products.
The agreement <a target="_blank" href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" rel="noreferrer noopener">will</a> dismiss all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. No financial payments are associated with the settlement from Abbott or Dexcom.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Analyst Reactions: William Blair writes that DME's market share remained steady in Q4, and productivity has improved as planned, following a 40% commercial team expansion last year.
The analyst says the management expects further gains in productivity and another record year for new patient additions in 2025.&nbsp;&nbsp;
While the benefits of these improvements will take several quarters to materialize, especially as 2024 execution challenges fade in the second half, analyst Margaret Kaczor Andrew sees multiple growth drivers that could boost performance in 2025 and sustain revenue and earnings growth in the long term.
Andrew said that DexCom's challenges in 2024 may be temporary. She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups.
However, the analyst points out that DexCom's growth depends on adding new patients, particularly those with early-stage diabetes, with limited clinical data and reimbursement support.
Competition from major players like Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) could also impact DexCom's expansion by capturing a share of new or existing patients in the continuous glucose monitoring market.
Morgan Stanley analyst Patrick Wood maintains DexCom with an Equal-Weight rating and raises the price <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">target from $75 to $82</a>.
Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and raises the price target from $99 to $103.
Price Action: DXCM stock is up 6.22% at $89.32 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer" target="_blank" rel="noreferrer noopener">Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer</a></li>
</ul>

Analyst Color

Earnings

Large Cap

News

Guidance

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

DXCM

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

February 11, 2025 records indicate that Representative Emily Randall filed a sale of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), valued between $11,011 and $165,000. According to the February filing, the transaction occurred on February 11, 2025.
Currently, Abbott Laboratories shares are trading down 0.85% at $130.32.
Want to keep up with Emily Randall and other congressional members' stock activities? Check out our <a href="https://www.benzinga.com/gov-trades/members/emily-randall">government trades tool</a> for real-time updates!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

Rep. Emily Randall Has Sold Up to $165K Worth Of Abbott Laboratories Stock: Here's What You Should Know

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has 14.97 million shares sold short, which is 0.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739280759_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 3.78%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Abbott Laboratories's Recent Short Interest

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.00</td>
<td>$168.9K</td>
<td>10.7K</td>
<td>17.1K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$93.00</td>
<td>$49.9K</td>
<td>25</td>
<td>604</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$130.00</td>
<td>$42.9K</td>
<td>6.5K</td>
<td>520</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$53.5K</td>
<td>1.9K</td>
<td>112</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$102.8K</td>
<td>436</td>
<td>56</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$45.0K</td>
<td>124</td>
<td>47</td>
</tr>
<tr>
<td>TMO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$650.00</td>
<td>$60.4K</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$65.7K</td>
<td>6</td>
<td>25</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$540.00</td>
<td>$27.6K</td>
<td>625</td>
<td>21</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding LXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 11262 contract(s) at a $1.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $168.9K, with a price of $15.0 per contract. There were 10734 open contracts at this strike prior to today, and today 17155 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a call option sweep that happens to be bearish, expiring in 24 day(s) on February 21, 2025. This event was a transfer of 316 contract(s) at a $93.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $49.9K, with a price of $158.0 per contract. There were 25 open contracts at this strike prior to today, and today 604 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 272 contract(s) at a $130.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $42.9K, with a price of $158.0 per contract. There were 6570 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 143 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $535.0 per contract. There were 1923 open contracts at this strike prior to today, and today 112 contract(s) were bought and sold. 
• Regarding AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we observe a call option trade with neutral sentiment. It expires in 24 day(s) on February 21, 2025. Parties traded 46 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $102.8K, with a price of $2235.0 per contract. There were 436 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For LNTH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), we notice a call option sweep that happens to be bullish, expiring in 143 day(s) on June 20, 2025. This event was a transfer of 47 contract(s) at a $100.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $968.0 per contract. There were 124 open contracts at this strike prior to today, and today 47 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a call option trade with bearish sentiment. It expires in 234 day(s) on September 19, 2025. Parties traded 30 contract(s) at a $650.00 strike. The total cost received by the writing party (or parties) was $60.4K, with a price of $2016.0 per contract. There were 70 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• Regarding REGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), we observe a call option trade with bullish sentiment. It expires in 52 day(s) on March 21, 2025. Parties traded 25 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $65.7K, with a price of $2630.0 per contract. There were 6 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 79 day(s) on April 17, 2025. This event was a transfer of 10 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $27.6K, with a price of $2760.0 per contract. There were 625 open contracts at this strike prior to today, and today 21 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AKRO

LNTH

LXRX

REGN

9 Health Care Stocks With Whale Alerts In Today's Session

Financial giants have made a conspicuous bearish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) revealed 20 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $250,731, and 18 were calls, valued at $6,957,978.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $135.0 for Abbott Laboratories over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Abbott Laboratories's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Abbott Laboratories's significant trades, within a strike price range of $75.0 to $135.0, over the past month.
<h3>Abbott Laboratories Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737999929_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$27.5</td>
<td>$23.0</td>
<td>$24.1</td>
<td>$115.00</td>
<td>$6.0M</td>
<td>3.6K</td>
<td>2.5K</td>
</tr>
<tr>
<td>ABT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$2.3</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$129.00</td>
<td>$190.8K</td>
<td>0</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$32.6</td>
<td>$31.15</td>
<td>$31.15</td>
<td>$105.00</td>
<td>$133.9K</td>
<td>278</td>
<td>43</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.05</td>
<td>$1.89</td>
<td>$2.05</td>
<td>$130.00</td>
<td>$101.9K</td>
<td>2.9K</td>
<td>2.4K</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$19.55</td>
<td>$19.15</td>
<td>$19.27</td>
<td>$115.00</td>
<td>$75.2K</td>
<td>376</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Following our analysis of the options activities associated with Abbott Laboratories, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Abbott Laboratories</h3>
<ul>
<li>Trading volume stands at 5,462,045, with ABT's price up by 3.42%, positioned at $129.31.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 79 days.</li>
</ul>
<h3>What The Experts Say On Abbott Laboratories</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $142.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Abbott Laboratories with a target price of $158. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Abbott Laboratories with a target price of $148. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $135. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $135. 
&#x2A; An analyst from Stifel persists with their Buy rating on Abbott Laboratories, maintaining a target price of $135. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Abbott Laboratories, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Markets

This Is What Whales Are Betting On Abbott Laboratories

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said he is worried about The Wendy&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>).
Cramer says it should not have a 7% yield, adding, &#8220;That, to me, suggests something may be wrong here.
Morgan Stanley analyst John Glass supported his view on Jan. 21, downgrading Wendy&#8217;s from Equal-Weight to Underweight and lowering the price target from $22 to $14.
<h3 class="wp-block-heading">Nu Is A &#8216;Really Hard&#8217; Company</h3>
Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) is a &#8220;really hard&#8221; company. Cramer added that he prefers SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) over the fintech firm.
Supporting his view, Citigroup analyst Ashwin Shirvaikar, on Dec. 2, downgraded the rating from Neutral to Sell on the stock and lowered its price <a href="https://www.benzinga.com/quote/NU/analyst-ratings">target from $14.6 to $11</a>.
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
TETRA Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTI#NYSE">TTI</a>) is a &#8220;very good company, and it did come up from the ashes,&#8221; Cramer said. &#8220;As a matter of fact, it's come up so much, it's up 28% for the year, so I cannot sanction buying it.&#8221;
The company's stock also jumped more than 33% over the past month.
When asked about Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), he said, &#8220;I can't recommend anything on a straight line. But if it pulls back a couple bucks, though, it's good, because this should be one of the great pharma stories because it's got the best growth in device and pharmaceuticals.&#8221;
Abbott Laboratories, meanwhile, on Jan. 22, reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
&#8220;This one has been around forever, and it just caught fire,&#8221; Cramer said when asked about Casella Waste Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWST#NASDAQ">CWST</a>). The &#8220;Mad Money&#8221; host added that although it's good he will go back to Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>).
Adding support to his choice, Jefferies analyst Stephanie Moore, on Jan. 23, downgraded Casella Waste from Buy to Hold and lowered the price target from $115 to $113.
Price Action:
<ul>
<li>TETRA Technologies shares fell 1.7% to settle at $4.60 on Friday.</li>
<li>Abbott shares gained 1.5% to close at $125.03 during the session.</li>
<li>Wendy's shares gained 0.6% to settle at $14.30 on Friday.</li>
<li>Nu Holdings shares rose 1.2% to close at $12.34.</li>
<li>Casella Waste shares slipped 1% to settle at $105.03 on Friday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/43189390/top-3-materials-stocks-that-may-fall-off-a-cliff-in-january">Top 3 Materials Stocks That May Fall Off A Cliff In January</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

CWST

SOFI

Jim Cramer Is Worried About This Consumer Cyclical Stock: 7% Yield? 'Something May Be Wrong Here'

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley slashed the price target for Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) from $56 to $11. Morgan Stanley analyst Terence Flynn downgraded the stock from Overweight to Equal-Weight. Intellia Therapeutics shares closed at $10.99 on Friday. <a href="https://www.benzinga.com/quote/NTLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut McCormick &amp; Company, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) price target from $85 to $82. Barclays analyst Andrew Lazar maintained an Equal-Weight rating. McCormick shares closed at $74.89 on Friday. <a href="https://www.benzinga.com/quote/MKC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised the price target for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) from $149 to $158. Barclays analyst Matt Miksic maintained an Overweight rating. Abbott shares closed at $125.03 on Friday. <a href="https://www.benzinga.com/quote/ABT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised the price target for Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from $77 to $185. Goldman Sachs analyst Kash Rangan upgraded the stock from Neutral to Buy. Twilio shares closed at $136.23 on Friday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut RLI Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLI#NYSE">RLI</a>) price target from $95 to $61. Jefferies analyst Andrew Andersen downgraded the stock from Buy to Underperform. RLI shares settled at $72.48 on Friday. <a href="https://www.benzinga.com/quote/RLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley raised Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) price target from $30 to $40. Morgan Stanley analyst Jefferson Harralson upgraded the stock from Equal-Weight to Overweight. Exelixis shares closed at $32.38 on Friday. <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan decreased Omnicom Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) price target from $119 to $116. JP Morgan analyst David Karnovsky maintained an Overweight rating. Omnicom shares closed at $86.56 on Friday.  <a href="https://www.benzinga.com/quote/OMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised the price target for Portillo&#8217;s Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLO#NASDAQ">PTLO</a>) from $13 to $16. Stifel analyst Chris O&#8217;Cull upgraded the stock from Hold to Buy. Portillo&#8217;s shares settled at $12.49 on Friday. <a href="https://www.benzinga.com/quote/PTLO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut RingCentral, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) price target from $45 to $37. Barclays analyst Ryan Macwilliams downgraded the stock from Overweight to Equal-Weight. RingCentral shares closed at $34.65 on Friday. <a href="https://www.benzinga.com/quote/RNG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) price target from $85 to $110. Piper Sandler analyst Harsh Kumar upgraded the stock from Neutral to Overweight. Qorvo shares closed at $88.94 on Friday. <a href="https://www.benzinga.com/quote/QRVO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/01/43189390/top-3-materials-stocks-that-may-fall-off-a-cliff-in-january">Top 3 Materials Stocks That May Fall Off A Cliff In January</a></li>
</ul>

Pre-Market Outlook

EXEL

NTLA

PTLO

QRVO

TWLO

Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $149 to $158.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $158

Investors with a lot of money to spend have taken a bearish stance on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 20 options trades for Abbott Laboratories.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $28,905, and 19, calls, for a total amount of $1,330,626.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $140.0 for Abbott Laboratories over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Abbott Laboratories's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Abbott Laboratories's whale trades within a strike price range from $60.0 to $140.0 in the last 30 days. 
<h3>Abbott Laboratories Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737743462_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.5</td>
<td>$29.5</td>
<td>$29.5</td>
<td>$105.00</td>
<td>$218.3K</td>
<td>365</td>
<td align="right">74</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$17.9</td>
<td>$17.7</td>
<td>$17.9</td>
<td>$115.00</td>
<td>$178.9K</td>
<td>823</td>
<td align="right">106</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.75</td>
<td>$29.7</td>
<td>$29.75</td>
<td>$105.00</td>
<td>$145.7K</td>
<td>365</td>
<td align="right">130</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$66.25</td>
<td>$65.45</td>
<td>$65.77</td>
<td>$60.00</td>
<td>$131.5K</td>
<td>0</td>
<td align="right">20</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.3</td>
<td>$9.1</td>
<td>$9.1</td>
<td>$140.00</td>
<td>$78.2K</td>
<td>1.1K</td>
<td align="right">88</td>
</tr>
</tbody>
</table>

<h3>About Abbott Laboratories</h3>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
After a thorough review of the options trading surrounding Abbott Laboratories, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Abbott Laboratories Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,249,687, the price of ABT is down by -0.19%, reaching $122.98.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
<h3>What The Experts Say On Abbott Laboratories</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $137.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Abbott Laboratories with a target price of $148. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Abbott Laboratories, which currently sits at a price target of $136. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $135. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $135. 
&#x2A; Maintaining their stance, an analyst from Stifel continues to hold a Buy rating for Abbott Laboratories, targeting a price of $135. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Abbott Laboratories with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on ABT Options

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $139.67, a high estimate of $149.00, and a low estimate of $135.00. Witnessing a positive shift, the current average has risen by 1.95% from the previous average price target of $137.00.
<img src="https://www.benzinga.com/files/images/story/2025/1737666047_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Abbott Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Lawrence Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$136.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$143.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Abbott Laboratories. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Abbott Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Abbott Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>About Abbott Laboratories</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Key Indicators: Abbott Laboratories's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Abbott Laboratories's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 4.85%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Abbott Laboratories's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 15.48%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Abbott Laboratories's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.16%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Abbott Laboratories's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.23%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.38.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Abbott Laboratories Stock: Analyst Perspectives (6 Ratings)

On Wednesday, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the <a href="https://www.benzinga.com/25/01/43131874/abbott-q4-sales-fall-short-of-estimates-issues-q1-profit-guidance-lower-than-street-view">consensus of $11.01 billion</a>.
Organic sales growth for the underlying base business was 8.8%. Organic growth, excluding COVID-19 testing-related sales was 10.1%.
Stifel analyst Rick Wise has a positive outlook on Abbott&#8217;s Q4 2024 results and its 2025 projections. He sees strong momentum in the Diabetes Care and Structural Heart segments, which are expected to drive double-digit growth in the Medical Device division and high-single-digit growth for the entire company.
Also Read: <a href="https://www.benzinga.com/news/large-cap/24/09/40738686/abbott-laboratories-recalls-some-sensors-for-its-popular-freestyle-libre-3-glucose-monitoring-syst">Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System</a>
CEO Robert Ford outlined key growth opportunities for the Diabetes Care division. These include increasing the use of continuous glucose monitors (CGMs) among insulin-intensive patients, expanding market share with the Libre system's insulin pump connectivity, and tapping into the consumer market with the Lingo CGM.
Additionally, Abbott expects to achieve 150 basis points of operating margin improvement, reflecting the success of its internal cost initiatives. This positions the company to sustain double-digit EPS growth over the long term.
Stifel analyst says Abbott's business divisions are offering more unique products, positioning the company for strong growth in the MedTech sector as the post-COVID recovery continues. They expect Abbott to improve its revenue and profits in the coming years, driven by better execution, the launch of key products across its franchises, and a sharper focus on generating cash and reducing debt.
Stifel maintains the Buy rating with a price forecast of $135, <a href="https://www.benzinga.com/quote/ABT/analyst-ratings">up from $130</a>.
Piper Sandler says the Q4 report was positive, with Abbott taking strong underlying performance into the new year. The analyst Adam Maeder remains constructive on shares and believes Abbott stock is arguably the best way to get exposure to GARP in large-cap MedTech. Piper reiterates the Overweight rating with a price forecast of $133.
Price Action: Abbott stock is up 3.7% at $122.15 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43168435/google-taps-htcs-talent-in-250-million-deal-to-lead-ar-vr-innovation">Google Taps HTC&#8217;s Talent in $250 Million Deal to Lead AR/VR Innovation</a></li>
</ul>
Image: Shutterstock

Why Is Abbott Stock Trading Higher On Thursday?

January 22, 2025 records indicate that Representative Thomas Kean filed a purchase of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), valued between $1,001 and $15,000. According to the January filing, the transaction occurred on January 22, 2025.
Currently, Abbott Laboratories shares are trading up 2.78% at $121.05.
<h3>What Representative Has Been Trading Recently</h3>
In the past three years, Thomas Kean made 68 stock trades totaling more than $320 thousand. The largest trades involved stocks like Aon and Johnson &amp; Johnson. Their most notable trades made recently include key transactions: 
<ul>
<li>Liberty Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYK#NASDAQ">LBTYK</a>): $15,001 - $50,000 Purchase</li>
<li>Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>): $1,001 - $15,000 Purchase</li>
<li>Pernod Ricard (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PRNDY#OTC">PRNDY</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Thomas Kean's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canadian Pacific Kansas</td>
<td>CP</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-12-27</td>
</tr>
<tr>
<td>Pernod Ricard</td>
<td>PRNDY</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2024-12-27</td>
</tr>
<tr>
<td>Alphabet</td>
<td>GOOG</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2024-12-19</td>
</tr>
<tr>
<td>Abbott Laboratories</td>
<td>ABT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2024-12-16</td>
</tr>
<tr>
<td>Franklin Resources</td>
<td>BEN</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2024-12-16</td>
</tr>
</tbody>
</table>
To keep an eye on Thomas Kean's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/thomas-kean">real-time tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>The Importance of Congressional Transactions</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBTYK

PERNOD RICARD S A SP/ADR by Pernod Ricard S.A.

PRNDY

Congressional Trading Report: Rep. Thomas Kean Bought Over $1K In Abbott Laboratories Stock

RBC Capital analyst Shagun Singh reiterates Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and maintains $135 price target.

Reiteration

RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $135 Price Target

WIIM

Abbott shares are trading higher after multiple analysts raised their price targets on the stock.

Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $133 to $136.

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $136

Stifel analyst Rick Wise maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $130 to $135.

Stifel Maintains Buy on Abbott Laboratories, Raises Price Target to $135

UBS analyst Danielle Antalffy maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $146 to $148.

UBS Maintains Buy on Abbott Laboratories, Raises Price Target to $148

U.S. stock futures were mixed on Thursday following Wednesday's rally. Futures of benchmark indices were lower except Dow Jones, which was marginally higher in premarket trade.
After being propelled to the brink of a record closing high on Wednesday the S&amp;P 500 index was poised to open lower according to futures.
The 10-year Treasury note yielded 4.63%, while the two-year note yielded 4.30%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> indicated a strong 99.5% probability that the Federal Reserve will hold interest rates steady at its upcoming meeting on Jan. 31, 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.52%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.20%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.02%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.19%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) both experienced negative premarket trading on Thursday. SPY fell 0.17% to $605.39, and QQQ declined 0.53% to $528.71, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
U.S. stocks <a href="https://www.benzinga.com/25/01/43152748/sp-500-hits-new-record-fear-among-us-investors-eases-but-fear-greed-index-remains-in-fear-zone">rallied </a>on Wednesday, with the S&amp;P 500 reaching a new all-time high, intraday.
Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Procter &amp; Gamble Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) both reported better-than-expected financial results, boosting market sentiment. Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), however, missed revenue expectations.
On the economic front, the U.S. mortgage applications saw a slight increase, but this had a limited impact on market movement.
While most sectors experienced declines, particularly utilities, real estate, and energy sectors fell the most. However, technology and communication services led gains.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.28%</td>
<td>20,009.34</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.61%</td>
<td>6,086.37</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.30%</td>
<td>44,156.73</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.61%</td>
<td>2,303.72</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The performance of the &#8216;Magnificent 7&#8217; companies will drive corporate earnings growth, according to the analysts at BlackRock because these firms possess robust balance sheets, significant cash reserves, and negative net debt, enhancing their resilience to rising interest rates.
&#8220;Even in a higher-rate environment, we still think stocks can keep pushing higher as long as fundamentals stay strong,&#8221; the note stated.
BlackRock&#8217;s current stance remains risk-on as it anticipates the broadening of the AI beneficiary pool. However, it will monitor for potential triggers that may necessitate a shift in investment strategy.
According to Jason Goepfert, consultant at White Oak Consultancy and the founder of SentimenTrader, the S&amp;P 500 index was headed toward a rebound from a two-month low to a record high in just seven sessions on Wednesday. However, it didn&#8217;t close at a fresh record.
If the S&amp;P 500 hits a new record high in Thursday&#8217;s session, it will be its second fastest rebound over eight sessions, with the first quickest rebound recorded on June 24, 1998.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Just barely missed yet another 97-year record in the S&amp;P 500. It was on track to cycle from a 2-month low to record high in only 7 sessions. If it does so tomorrow (8 sessions), the only date that had a quicker rebound was Jun 24, 1998.
&mdash; Jason Goepfert (@jasongoepfert) <a href="https://twitter.com/jasongoepfert/status/1882172063668166940?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a> 
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on for the rest of the week:
<ul>
<li>On Thursday, initial jobless claims data till Jan. 18, will be released at 8:30 a.m. ET.</li>
</ul>
<ul>
<li>On Friday, S&amp;P flash services PMI and manufacturing PMI will be released at 9:45 a.m. ET.</li>
</ul>
<ul>
<li>Existing home sales for December and consumer sentiment data for January will be released at 10 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) was up 13.03% in premarket on Thursday ahead of its earnings before the opening bell. Analysts expect it to report quarterly earnings of $1.04 per share on revenue of $9.60 billion.</li>
</ul>
<ul>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) was up 0.75% as Wall Street expects it to report quarterly earnings of 64 cents per share on revenue of $13.40 billion before the opening bell.</li>
</ul>
<ul>
<li>Union Pacific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) was up 0.29% ahead of its earnings before the opening bell. Analysts expect it to report quarterly earnings of $2.78 per share on revenue of $6.14 billion.</li>
</ul>
<ul>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) was down 11.43% after it reported lower-than-expected first-quarter sales results and issued second-quarter revenue guidance below estimates.</li>
</ul>
<ul>
<li>Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) was up 5.45% in premarket as it posted better-than-expected fourth-quarter adjusted earnings results.</li>
</ul>
<ul>
<li>Vince Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) was up 47.23% as P180 acquired Sun Capital's majority stake in the company. Brendan Hoffman is expected to become CEO effective Feb. 3, replacing interim CEO David Stefko, who will remain on the board.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.13% to hover around $75.34 per barrel.
The gold spot index was down by 0.53% to $2,756.26 per ounce. The Dollar Index was up 0.01% at 108.20 level.
Asian markets closed mixed on Thursday as Hong Kong's Hang Seng, Australia's ASX 200, and South Korea's Kospi index fell. Whereas, China's CSI 300, and Japan's Nikkei 225 index rose. European markets were also mixed.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/01/43073354/warren-buffett-openly-called-bitcoin-a-rat-poison-in-2018-7-years-later-he-is-invested-in-this-crypto-linked-stock-which-soared-27-in-2024">Warren Buffett Openly Called Bitcoin A &#8216;Rat Poison&#8217; In 2018. 7 Years Later, He Is Invested In This Crypto-Linked Stock Which Soared 27% In 2024</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Futures

NFLX

PLXS

VNCE

US Stock Futures Trade Mixed After Skirting Record Highs In Last Session: GE Aerospace, American Airlines, Union Pacific In Focus

The CNN Money Fear and Greed index showed further improvement in overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Wednesday.
U.S. stocks settled higher on Wednesday, with the S&amp;P 500 surging to a new all-time high during the session.
Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected fourth-quarter financial results on Tuesday. Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) posted better-than-expected second-quarter financial results. Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
On the economic data front, U.S. mortgage applications rose 0.1% from the previous week in the week ending Jan. 17.
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, real estate, and energy stocks recording losses on Wednesday. However, information technology and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 131 points to 44,156.73 on Wednesday. The S&amp;P 500 rose 0.61% to 6,086.37, while the Nasdaq Composite climbed 1.28% at 20,009.34 during Wednesday's session.
Investors are awaiting earnings results from GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), and Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 43.3, the index remained in the &#8220;Fear&#8221; zone on Wednesday, versus a prior reading of 41.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>
Photo courtesy: Shutterstock

S&P 500 Hits New Record As Netflix Reports Strong Results: Investor Sentiment Improves But Greed Index Remains In 'Fear' Zone

The S&amp;P 500 briefly hit 6,100 points on Wednesday, reaching a fresh all-time high as Wall Street embraced a powerful mix of strong corporate earnings and President Donald Trump's bold $500 billion artificial intelligence<a href="https://www.benzinga.com/25/01/43139410/softbanks-role-in-500-billion-stargate-ai-venture-seen-as-major-growth-driver-analyst-says"> initiative, dubbed &#8220;AI Stargate.&#8221; </a>
The project, designed to transform America's AI infrastructure, added fuel to a market already cheering on stronger-than-expected fourth-quarter earnings and rising hopes of Federal Reserve interest rate cuts later this year.
Mega-cap technology stocks and semiconductor giants led the charge, pushing the S&amp;P 500 — tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — higher for the sixth time in the last seven sessions.
By midday Wednesday, the S&amp;P 500 hit 6,100.4 points, narrowly surpassing its previous record of 6,099 set on Dec. 6.
See Also: <a href="https://www.benzinga.com/25/01/43142623/happy-birthday-sp-500-spy-etf-if-you-invested-1000-in-spy-at-launch-heres-how-much-youd-have-today">Happy Birthday S&amp;P 500 SPY ETF! If You Invested $1,000 In SPY At Launch, Here&#8217;s How Much You&#8217;d Have Today</a>
<h3 class="wp-block-heading">AI Stargate: A Game-Changing Investment in AI Infrastructure</h3>
Trump unveiled AI Stargate on Jan. 21. The joint venture unites OpenAI, led by Sam Altman, SoftBank, backed by Masayoshi Son, and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to build next-generation AI infrastructure.
The project aims to invest up to $500 billion over four years to develop massive AI data centers across the U.S., starting with an initial $100 billion phase.
Trump hailed the initiative as a &#8220;declaration of confidence in America&#8217;s potential,&#8221; emphasizing its importance in keeping the future of AI technology within U.S. borders. 
AI Stargate is expected to create 100,000 jobs almost immediately, further boosting optimism about economic growth.
<h3 class="wp-block-heading">Earnings Strength Fuels Market Optimism</h3>
While AI excitement dominated headlines, a strong corporate earnings season provided the foundation for the market&#8217;s rally. 
As of Jan. 17, 81% of S&amp;P 500 companies reporting fourth-quarter results had exceeded Wall Street's profit forecasts, while 64% had beaten revenue estimates, according to FactSet.
Mega-cap firms reporting earnings this week — including Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>), Prologis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>), Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) — all topped estimates, reinforcing investor confidence in corporate America&#8217;s strength.
&#8220;The S&amp;P 500's forward profit margin was at a record-high 13.6% during the January 18, 2025, week, up 0.9 percentage points from 12.7% a year earlier,&#8221; veteran investor Ed Yardeni said in a note Wednesday. 
&#8220;Corporate profitability should continue to improve even as Trump's administration faces a big fiscal headwind.&#8221;
<h2 class="wp-block-heading">Tech Titans Drive The Market Higher</h2>
The so-called &#8220;Magnificent 7&#8221; stocks were at the center of Wednesday's rally, with the Roundhill Magnificent Seven ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#NASDAQ">MAGS</a>) climbing 1.5%.
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) surged 4%, while Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) jumped 4.6%, reinforcing their dominance in the AI race. Chip stocks saw particularly strong gains as investors bet on increased demand for AI-related infrastructure. 
Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), the SoftBank-owned semiconductor design firm, soared 15%—its biggest single-day gain since February 2024.
SoftBank's 2024 annual report had described Arm as providing &#8220;the foundational technology for Artificial Super Intelligence,&#8221; a claim that now appears increasingly relevant as AI Stargate takes shape.
<h3 class="wp-block-heading">Six Stocks Powering The S&amp;P 500's Record High</h3>
Just a handful of companies were responsible for a significant portion of the broader market's surge on Wednesday. 
Nvidia and Microsoft alone contributed 53 basis points to the S&amp;P 500&#8217;s advance, while Netflix, Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Oracle Corp. collectively added another 18 basis points.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Security Name</th>
<th>Price</th>
<th>Weight in S&amp;P 500</th>
<th>1-day %chg</th>
<th>Contribution to S&amp;P 500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nvidia Corp.</td>
<td>$1,472.46</td>
<td>6.51%</td>
<td>4.55%</td>
<td>+29bp</td>
</tr>
<tr>
<td>Microsoft Corp.</td>
<td>$445.37</td>
<td>6.27%</td>
<td>3.94%</td>
<td>+24bp</td>
</tr>
<tr>
<td>Netflix Inc.</td>
<td>$952.64</td>
<td>0.72%</td>
<td>9.54%</td>
<td>+6bp</td>
</tr>
<tr>
<td>Amazon.com Inc.</td>
<td>$233.46</td>
<td>4.10%</td>
<td>1.19%</td>
<td>+5bp</td>
</tr>
<tr>
<td>Meta Platforms Inc.</td>
<td>$626.13</td>
<td>2.65%</td>
<td>1.57%</td>
<td>+4bp</td>
</tr>
<tr>
<td>Oracle Corp.</td>
<td>$184.92</td>
<td>0.51%</td>
<td>7.15%</td>
<td>+3bp</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43059744/exclusive-can-sp-500-repeat-large-gains-from-donald-trumps-first-term-a-second-time-around-readers-say-this-return-range-most-likely" target="_blank" rel="noreferrer noopener">Can S&amp;P 500 Repeat Large Gains From Trump's First Term A Second Time Around? Readers Say This&#8230;</a></li>
</ul>
Image: Shutterstock

Asia

Regulations

Broad U.S. Equity ETFs

Econ #s

Tech

ETFs

AMZN

MAGS

MSFT

NVDA

ORCL

SCHW

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run

The healthcare industry is poised for growth driven by aging populations, technological advancements, and increased healthcare spending. Hence, investors might consider investing in healthcare stocks, such as UnitedHealth Group (UNH), Abbott Laboratories (ABT), and Medtronic (MDT), which address the needs of the aging population. Read more… The growth of the healthcare services market is expected to be driven by factors such as the rising elderly population, accelerated economic growth, technological innovations, changing lifestyles, and improved survival rates and living standards.
Given this backdrop, it could be wise to consider investing in fundamentally strong healthcare stocks, UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>), Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>), and Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>).
The growing elderly population is increasing the need for long-term care services, including medical devices and consumables. Meanwhile, economic growth and lifestyle shifts are contributing to a rise in healthcare expenditures, especially on medical devices and consumables. The healthcare services market is forecast to grow at a <a href="https://www.technavio.com/report/healthcare-services-market-industry-analysis">CAGR of 8.7% by 2028</a>.
Additionally, <a href="https://www.precedenceresearch.com/healthcare-it-market">artificial intelligence revolutionized the healthcare</a> domain by impacting its several divisions and providing assistance in surgeries, diagnostics, personalized treatment plans, etc. AI-powered tools and techniques help to improve radiology, medical imaging, and drug discovery and development.
Given these favorable industry trends, let's look at the fundamentals of three healthcare stocks.
UnitedHealth Group Incorporated (<a href="https://stocknews.com/stock/UNH/">UNH</a>)
UNH operates as a diversified healthcare company in the United States. The company operates through four segments: UnitedHealthcare; Optum Health; Optum Insight; and Optum Rx.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBIT margin</a>, UNH's 8.07% is 215.7% higher than the 2.56% industry average. Likewise, its 3.40% trailing-12-month levered FCF margin is 47.5% higher than the 2.31% industry average. Its 8.07% trailing-12-month EBIT margin is 215.7% higher than the 2.56% industry average.
During the fourth quarter ended December 31, 2024, UNH's total revenues increased by 6.8% year-over-year to $100.81 billion. The company's net earnings were $5.78 billion, or $5.98 per share, up 1.9% and 2.6% year-over-year, respectively.
The consensus revenue estimate of $111.64 billion for the fiscal first quarter (ending March 2025) represents an 11.9% increase year-over-year. The company expects its EPS to increase 5.6% year-over-year to $7.29. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in each of the trailing four quarters.
Over the past year, the stock has surged 7.4%, closing the last trading session at $548.18.
UNH's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
UNH has a B grade for Stability, Quality, and Growth. It is ranked #3 out of 10 stocks in the <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry. <a href="https://stocknews.com/stock/UNH/">Click here</a> to see the additional ratings for UNH (Value, Momentum, and Sentiment).
Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT discovers, develops, manufactures, and sells healthcare products worldwide. It operates in four segments: Established Pharmaceutical Products; Diagnostic Products; Nutritional Products; and Medical Devices.
In terms of the trailing-12-month levered FCF margin, ABT's 15.24% is 573.4% higher than the 2.31% industry average. Its 0.56x trailing-12-month asset turnover ratio is 36.4% higher than the 0.41x industry average. Similarly, the stock's 16.82% trailing-12-month EBIT margin is 558.1% higher than the 2.56% industry average.
For the fourth quarter of 2024, which ended on December 31, 2024, ABT's revenue increased 7.2% year-over-year to $10.97 billion. Its net earnings increased considerably year-over-year to $9.23 billion and $5.27 per share, respectively.
Street expects ABT's revenue and EPS for the fiscal first quarter (ending March 2025) to increase 4.2% and 8.6% year-over-year to $10.38 billion and $1.06, respectively. Moreover, it beat the revenue and EPS estimates in three of the trailing four quarters, which is promising.
Shares of ABT have gained 14.6% over the past year to close the last trading session at $128.45.
ABT's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
ABT has an A grade for Stability and a B for Quality. It is ranked #7 out of 131 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry.
In addition to the POWR Ratings we've stated above, we also have ABT ratings for Momentum, Growth, Value, and Sentiment. Get all ABT ratings <a href="https://stocknews.com/stock/ABT/">here</a>.
Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
MDT develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
On January 13, 2025, MDT announced that the Centers for Medicare &amp; Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension. 
In terms of the trailing-12-month levered FCF margin, MDT's 15.19% is 487.7% higher than the 2.58% industry average. Its 65.40% trailing-12-month gross profit margin is 12.8% higher than the 58% industry average. Similarly, the stock's 19.77% trailing-12-month EBIT margin is 658.1% higher than the 2.61% industry average.
For the second quarter that ended on October 25, 2024, MDT's net sales rose 4.9% year-over-year to $8.40 billion. Its net income grew 12.8% from the year-ago value to $1.28 billion. In addition, the company's EPS stood at $1.27 billion, or $0.99 per share.
The consensus revenue estimate of $8.33 billion for the fiscal third quarter (ending January 2025) represents a 2.9% increase year-over-year. The consensus EPS estimate of $1.36 for the same quarter indicates a 4.6% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past six months, the stock has surged 11.1%, closing the last trading session at $90.53.
MDT's POWR Ratings reflect its bright outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
MDT has a B grade for Stability and Value. It is ranked #27 out of 131 stocks in the Medical - Devices &amp; Equipment industry. <a href="https://stocknews.com/stock/MDT/">Click here</a> to see the additional ratings for MDT (Growth, Sentiment, Momentum, and Quality).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
UNH shares were trading at $547.16 per share on Tuesday afternoon, down $1.02 (-0.19%). Year-to-date, UNH has gained 8.16%, versus a 2.70% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/unh-abt-mdt-3-healthcare-stocks-addressing-aging-population-needs/>3 Healthcare Stocks Addressing Aging Population Needs</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks Addressing Aging Population Needs

FDA advises diabetes device users to check alert settings

Long-term investors can create intergenerational wealth with dividend growth investing.

3 Dividend Growth Stocks For Intergenerational Wealth

Our Real-Life Market-Beating U.S. Stock Portfolio, Ten Years After

New insider activity at Abbott Laboratories ( ($ABT) ) has taken place on February 8, 2025. Chairman & CEO Robert Ford has made a significant trans...

Comments

Abbott Laboratories

Intérêt court

Abbott Laboratories (NYSE:ABT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL